Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 (NCT01597414)
Chemotherapy and HER2 targeted agents can improve survival significantly in metastatic breast cancer. Chemotherapy however is associated with significant side-effects and can impact on Quality of Life and functionality in older patients.
The investigators aim to establish HER2 targeted regimens with minimal toxicity in order to delay or even avoid the use of classical chemotherapy because of competing risks of death in this frail/elderly patient group.
This trial is sponsored by European Organisation for Research and Treatment of Cancer (EORTC) / F. Hoffmann-La Roche. 
- Condition: Elderly Metastatic Breast Cancer
- Phase: II
- Estimated Enrollment: 80
- Start: June 2013
- Estimated Primary Completion: November 2016
- Last verified: January 2015
* The name metronomic comes from the idea of regular administration of chemotherapeutic drugs.
The concept of Metronomic Chemotherapy or MCT, which is intended to prevent tumor angiogenesis, is based on research by Douglas Hanahan, Judah Folkman and Robert Kerbel and their respective colleagues. This approach stand in contradiction to traditional chemotherapy regimens which generally call for higher doses of chemotherapy and are often limited largely by the body’s own capacity to handle the adverse events as well as for limited campaigns of several weeks in order to avoid drug resistance and avoid harming the body’s organs beyond a certain limit. Hence, metronomic chemotherapy, which uses conventional cytotoxic drugs but counts on them to stop or slow blood vessel growth, makes reference to the chronic, equally spaced administration of low doses of various chemotherapeutic drugs without extended rest periods between cycles of therapy (a practice that may not only involve re-growth of tumour cells, but also growth of selected clones resistant to the therapy).
Metronomic Chemotherapy (MCT) contrasts the Maximum Tolerated Dose (MTD) method typically used in most clinical protocols.
Last Editorial review: July 30, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.